<?xml version="1.0" encoding="UTF-8"?>
<ref id="b10-1031308">
 <label>10.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cooper</surname>
    <given-names>TM</given-names>
   </name>
   <name>
    <surname>Sison</surname>
    <given-names>EAR</given-names>
   </name>
   <name>
    <surname>Baker</surname>
    <given-names>SD</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03)</article-title>. 
  <source>Pediatr Blood Cancer</source>. 
  <year>2017</year>;
  <volume>64</volume>(
  <issue>8</issue>).
 </mixed-citation>
</ref>
